Avalanche Biotechnologies
Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL)[1] biotechnology company in the NASDAQ Biotechnology Index that is worth 245 million that is dedicated to diseases of the eye/.[2] Its products are dedicated to treating macular degeneration,[3] Retinal Vein Occluision,[4]Diabetic Macular Edema,[5] and many more diseases.[6]
| Product Name | Indication | Clinical Trial Phase | Partnership? If so with whom |
|---|---|---|---|
| AVA-101 | age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | Preclinical | No |
| AVA-201 | age-related macular degeneration | Theoretical research | No |
| AVA-322 AVA-323 | Color Vision Deficiency | Preclinical | No |
| AVA-311 | X-linked Retinoschisis | Preclinical | Regeneron |
References
- ↑ "Avalanche Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
- ↑ "Avalanche Biotechnologies Announces Leadership Transition". www.reuters.com. Retrieved 4 January 2016.
- ↑ "Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? - Avalanche Biotechnologies (NASDAQ:AAVL)". Seeking Alpha. Retrieved 4 January 2016.
- ↑ Burger, Danielle. "Avalanche Drops as Gene Therapy Data Miss High Expectations". Bloomberg.com.
- ↑ "Update on the latest in business:". WTOP. Tegna Media. Retrieved 4 January 2016.
- ↑ Burger, Danielle. "Avalanche drops eye drug trial, takes it back to lab". CNBC.
This article is issued from Wikipedia - version of the Thursday, March 24, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.